Invitae Corporation (NVTA): Price and Financial Metrics

Invitae Corporation (NVTA): $2.44

-0.12 (-4.69%)

POWR Rating

Component Grades














  • NVTA scores best on the Growth dimension, with a Growth rank ahead of 73.54% of US stocks.
  • The strongest trend for NVTA is in Stability, which has been heading down over the past 178 days.
  • NVTA's current lowest rank is in the Sentiment metric (where it is better than 5.78% of US stocks).

NVTA Stock Summary

  • Of note is the ratio of INVITAE CORP's sales and general administrative expense to its total operating expenses; just 5.22% of US stocks have a lower such ratio.
  • In terms of twelve month growth in earnings before interest and taxes, INVITAE CORP is reporting a growth rate of 666.21%; that's higher than 97.5% of US stocks.
  • The volatility of INVITAE CORP's share price is greater than that of 97.05% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to NVTA, based on their financial statements, market capitalization, and price volatility, are SSRM, MUR, AEM, MSTR, and IAG.
  • Visit NVTA's SEC page to see the company's official filings. To visit the company's web site, go to

NVTA Valuation Summary

  • NVTA's price/sales ratio is 1.9; this is 65.45% lower than that of the median Healthcare stock.
  • Over the past 92 months, NVTA's EV/EBIT ratio has gone up 18.

Below are key valuation metrics over time for NVTA.

Stock Date P/S P/B P/E EV/EBIT
NVTA 2022-09-09 1.9 2.4 -0.3 -0.8
NVTA 2022-09-08 1.5 2.0 -0.2 -0.7
NVTA 2022-09-07 1.5 1.9 -0.2 -0.7
NVTA 2022-09-06 1.3 1.7 -0.2 -0.7
NVTA 2022-09-02 1.3 1.7 -0.2 -0.7
NVTA 2022-09-01 1.4 1.8 -0.2 -0.7

NVTA Growth Metrics

    The 2 year cash and equivalents growth rate now stands at 247.55%.
  • Its 3 year net cashflow from operations growth rate is now at -604.62%.
  • Its 3 year price growth rate is now at -76.66%.
Over the past 70 months, NVTA's revenue has gone up $481,856,000.

The table below shows NVTA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 500.829 -623.202 -3,108.62
2022-03-31 480.519 -617.838 -451.373
2021-12-31 460.449 -559.815 -379.006
2021-09-30 434.759 -497.479 -408.22
2021-06-30 389.092 -394.593 -312.946
2021-03-31 318.971 -325.662 -613.135

NVTA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVTA has a Quality Grade of D, ranking ahead of 13.88% of graded US stocks.
  • NVTA's asset turnover comes in at 0.118 -- ranking 73rd of 81 Healthcare stocks.
  • BKD, VCYT, and HCSG are the stocks whose asset turnover ratios are most correlated with NVTA.

The table below shows NVTA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.118 0.281 -0.331
2021-03-31 0.139 0.268 -0.887
2020-12-31 0.183 0.291 -1.070
2020-09-30 0.284 0.321 -0.721
2020-06-30 0.280 0.347 -0.790
2020-03-31 0.336 0.429 -0.705

NVTA Stock Price Chart Interactive Chart >

Price chart for NVTA

NVTA Price/Volume Stats

Current price $2.44 52-week high $32.22
Prev. close $2.56 52-week low $1.83
Day low $2.37 Volume 6,403,900
Day high $2.53 Avg. volume 11,393,465
50-day MA $3.12 Dividend yield N/A
200-day MA $6.78 Market Cap 574.05M

Invitae Corporation (NVTA) Company Bio

Invitae Corporation is a company that utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The company was founded in 2012 and is based in San Francisco, California.

NVTA Latest News Stream

Event/Time News Detail
Loading, please wait...

NVTA Latest Social Stream

Loading social stream, please wait...

View Full NVTA Social Stream

Latest NVTA News From Around the Web

Below are the latest news stories about INVITAE CORP that investors may wish to consider to help them evaluate NVTA as an investment opportunity.

Why Invitae Stock Is Jumping Today

Shares of Invitae (NYSE: NVTA) were jumping 6.7% higher as of 10:53 a.m. ET on Wednesday after rising as much as 12.9% earlier in the morning. On Tuesday, though, Invitae and Praxis Precision Medicines stated in a press release that Invitae's Citizen platform's clinical insights were used in Praxis' Investigational New Drug (IND) application for experimental drug PRAX-222 in treating epilepsy. Invitae's shares fell 5% yesterday.

Yahoo | September 21, 2022

Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing

First use of Ciitizen platform as source of real-world data in regulatory filingSAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developm

Yahoo | September 20, 2022

Leading Clinical Experts Across the U.S. Unite to Support Universal Genetic Testing for all Patients with Cancer

Invitae (NYSE: NVTA), a leading medical genetics company, joined other clinical experts in releasing a new commentary in Journal of Clinical Oncology Precision Oncology, underscoring the importance of universal germline testing for all patients with cancer (solid tumors). The paper reports a meta-analysis of multiple clinical publications supporting universal testing, independent of age, stage, family history or type of cancer. It reports that for cancer types such as pancreatic and ovarian wher

Yahoo | September 15, 2022

Why Shares of Invitae Dropped 13% on Tuesday

Shares of Invitae (NYSE: NVTA), a maker of medical genetic tests, fell 14% on Tuesday. Invitae's shares have been highly volatile and, earlier this month, shot up 277% the day it released second-quarter earnings. The drop comes a day after the company announced a collaboration with international research program Simons Searchlight.

Yahoo | September 13, 2022

Invitae and Simons Searchlight Partner to Accelerate Research through Data Sharing

Invitae (NYSE: NVTA), a leading medical genetics company, today announced a collaboration with Simons Searchlight, an international research program with a goal of accelerating research and improving lives for people with rare genetic neurodevelopmental disorders. This partnership will connect two sets of data – the longitudinal clinical data extracted from medical records through Invitae's Ciitizen, a patient-consented, digital natural history data platform and patient reported outcomes and bio

Yahoo | September 12, 2022

Read More 'NVTA' Stories Here

NVTA Price Returns

1-mo -23.51%
3-mo -15.57%
6-mo -72.40%
1-year -91.88%
3-year -87.32%
5-year -72.71%
YTD -84.02%
2021 -63.48%
2020 159.21%
2019 45.84%
2018 21.81%
2017 14.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4841 seconds.